Novo Nordisk Heart Drug Ziltivekimab Fails in ZEUS Trial
Novo Nordisk announced on July 31, 2026, that its experimental heart drug ziltivekimab failed to reduce heart attacks, strokes, or cardiovascular deaths in the large ZEUS trial. The neutral result across more than 6,300 patients challenges the longstanding medical theory that dampening chronic inflammation alone protects the heart. The ZEUS Trial Results and the Failure … Read more